Co-Founder of BioWare: Guest Ray Muzyka

Aug 11, 2020 | Podcast


Ray Muzyka co-founded BioWare in the early 1990s after completing his MD. He practiced full-time rural locum tenens Emergency/Family Med for two years, then medicine transitioned to part-time rural locums for the next decade as his second career for the next two decades focused on his role as BioWare’s CEO.

BioWare was the fastest growing company in Alberta in 2002 and has won many industry awards for quality/innovation, and multiple years on Canada’s Top 100 Employers Awards.

BioWare received its first external (private equity) funding from Elevation Partners in 2005. After acquisition by Electronic Arts in 2007, in 2009 Muzyka was promoted to SVP/Group GM of EA’s BioWare Label which by 2012 had eight studios, ~$500MM USD annual revenues, and ~2000 FT+PT staff worldwide.

Ray retired after 20 years in videogames in late 2012, with his third career chapter at ThresholdImpact ( mentoring entrepreneurs in medical innovations and social enterprise technology. He is an active angel impact investor ( across North America.

Dr. Muzyka obtained his BMedSc from UAlberta in 1990, his MD from the U of A in 1992 and CCFP in 1994, and his MBA from the Ivey School of Business (UWO) in 2001.

He is a member of YPO, A100, Founding Chair of UAlberta Venture Mentoring Service, Venture Advisor and Investment Committee Member at iNovia, Advisory Board Member at Voyager Capital, Public Member on the U of A Board of Governors, is a mentor Fellow at CDL West, Rockies and Toronto, is a CDL-Global Founding Partner, and serves on multiple private company boards.

He was inducted into the Order of Canada in 2018, AIAS’s Hall of Fame in 2011, Alberta’s Business Hall of Fame in 2018, received GDC’s 2013 Lifetime Achievement Award, Canada’s Top 40 under 40, E&Y’s Entrepreneur of the Year (Prairies), U of A’s 2015 Alumni Innovation Award, MacEwan’s 2017 Allard Chair in Business, among other awards.

Join Zoic's Newsletter

Our team of industry experts and professionals provide industry news, guidance and perspective within the life sciences and medtech investment sectors. To see the type of deals and company innovation we pay attention to, consider receiving our biweekly deal flow newsletter.